Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Subjects with advanced/metastatic Colorectal Cancer(CRC) who have failed or been intolerant to both irinotecan- and oxaliplatin- based regimens * Subjects with advanced/metastatic Squamous cell carcinoma of the head and neck (SCCHN) who are without options for curative treatment * Subjects must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria * Men and women 18 and older * Women of childbearing potential (WOCBP) and men must use highly effective methods of contraception * Eastern Cooperative Oncology Group (ECOG) of 0 or 1 * Subjects must have a life expectancy of at least 3 months Exclusion Criteria: * Active or progressing brain metastases * Other concomitant malignancies (with some exceptions per protocol) * Nasopharyngeal carcinoma * Active or history of autoimmune disease * Positive test for Human Immunodeficiency Virus (HIV) 1\&2 or known AIDS * History of any hepatitis (A,B or C) * Known current drug or alcohol abuse * Active Tuberculosis (TB) * Use of anti-cancer treatments within 28 days * Prior therapy with anti-CD137 antibody Other protocol defined inclusion/exclusion criteria could apply